|
Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma. Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma. conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma. Clinical research trials and Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma. health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma.. Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma. Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma. clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma. condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma.  Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma.
Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma.
For Condition: Lymphoma, Non-Hodgkin
Status: No longer recruiting
Sponsor(s): Chiron Corporation ,
Synopsis: The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion: - Diagnosis: CD20+ B-cell non-Hodgkin's lymphoma (NHL) classified as intermediate- or high-grade according to the Working Formulation, subtypes D to H. Must have measureable progressive or refractory disease after no more than three prior chemotherapy regimens. Exclusion: - Clinically significant cardiac dysfunction, or a history of myocardial infarction or heart failure within 6 months of first study treatment - Clinically significant pulmonary dysfunction. - Liver disease (note hepatitis C seropositive subjects may be enrolled if they have no active disease as demonstrated by undetectable HCV viral loads, biopsy showing no active disease, and/or history of normal transaminases on at least three different dates within one year of first study treatment). - Symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism. - History of autoimmune disease. - History of positive serology for human immunodeficiency virus (HIV).
Total Enrollment:
Location and Contact Information:
Stanford University Medical Center
Stanford, California, 94305-5151
United States
California Cancer Medical Center
West Covina, California, 91790
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States
Dartmouth-Hitchcock-Medical Center
Lebanon, New Hampshire, 03756
United States
Oregon Heath and Science University
Portland, Oregon, 97201
United States
Cancer Specialists of South Texas, P.A.
Corpus Christi, Texas, 78412
United States
Roger Maris Health System
Fargo, North Dakota, 58122
United States
Cancer Centers of the Carolinas
Greenville, South Carolina, 29615
United States
Cancer Care Center
Bloomington, Indiana, 47403
United States
John Wayne Cancer Institute
Santa Monica, California, 90404
United States
Germantown Cancer Center
Germantown, Tennessee, 38138
United States
Memorial Sloan Kettering Cancer Center
New York City, New York, 10021
United States
Consultants in Blood Disorders and Cancer
Louisville, Kentucky, 40207
United States
Northwestern University, Feinberg School of Medicine
Chicago, Illinois, 60611
United States
Kansas City Oncology and Hematology Group
Kansas City, Missouri, 64111
United States
UC Davis Cancer Center
Sacramento, California, 95817
United States
Oncology Hematology Care Inc.
Cincinnati, Ohio, 45242
United States
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195
United States
Gabrail Cancer Center
Canton, Ohio, 44718
United States
Arch Medical Group, LLC
St. Louis, Missouri, 63141
United States
Virginia Cancer Institute
Richmond, Virginia, 23230
United States
Our Lady of Mercy Medical Center, Comprehensive Cancer Center
Bronx, New York, 10466
United States
Washington Cancer Institute
Washington D.C., District of Columbia, 20010
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
East Carolina University School of Medicine/ Division of Hematology/Oncology
Greenville, North Carolina, 27858
United States
Division of Hematology/Oncology, University of Miami School of Medicine
Miami, Florida, 333136
United States
Oncology Specialists, S.C.
Park Ridge, Illinois, 60068
United States
Hematology /Oncology Consultants Inc.
Columbus, Ohio, 43235
United States
Rush Cancer Institute
Chicago, Illinois, 60612
United States
ACRC/Arizona Clinical Research Center, Inc.
Tucson, Arizona, 85712
United States
Hoag Cancer Center
Newport Beach, California, 92658
United States
Georgetown University Medical Center, Lombardi Cancer Center
Washington D.C., District of Columbia, 20007
United States
Louisiana Health Sciences Center, Department of Medicine, Hematology/Oncology
Shreveport, Louisiana, 71130
United States
Additional Information:
Study ID Numbers: IL2NHL05;
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00045864
Other Lymphoma, Non-Hodgkin Studies:
1. A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines
2. Evaluation of Bay 59-8862 in Patients with Aggressive, Refractory Non-Hodgkin's Lymphoma
3. Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
4. Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma
5. A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant
Related Studies:
Other Lymphoma, Non-Hodgkin Clinical Trials
Other Missouri Clinical Trials
Other St. Louis Clinical Trials
Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma.
|
|
|
|
|
|
|
|
